Dual Antiplatelet Therapy beyond 12 Months Versus for 12 Months after Drug-Eluting Stents for Acute Myocardial Infarction

Jeong, Myung Ho

Dual Antiplatelet Therapy beyond 12 Months Versus for 12 Months after Drug-Eluting Stents for Acute Myocardial Infarction

Tuesday, May 21, 2019

Belmont Ballroom 2-3 (The Cosmopolitan of Las Vegas)

Myung Ho Jeong, M.D., Ph.D., FSCAI , Chonnam National University Hospital, Gwangju, South Korea

Youngkeun Ahn, M.D., Ph.D., FSCAI , Chonnam National University Hospital, Gwangju, South Korea

Taehoon Ahn, M.D. , Gachon University Hospital, Heart Center, Inchon, Korea, South

Kwang Soo Cha, M.D., Ph.D. , Pusan Natinal University Hospital, Busan, Korea, South

Background
The optimal duration of dual antiplatelet therapy (DAPT) after acute myocardial infarction (AMI) remains uncertain. This study investigated the benefit of DAPT beyond 12 months after drug-eluting stents (DES) for AMI.

Methods
From Korea Acute Myocardial Infarction Registry (KAMIR), 6,741 patients treated with DAPT for 12 months after DES without ischemic or bleeding events were analyzed.

Results
After adjustment using inverse probability of treatment weighting, patients who received DAPT beyond 12 months (n = 4,796), compared to patients treated with 12-month DAPT (n = 1,945), had a similar incidence of MACCE (1.3% vs. 0.9%, HR: 1.39, 95% CI: 0.80 to 2.42, p = 0.249). The rate of net adverse clinical events was 1.4% with DAPT beyond 12 months and 1.1% with 12-month DAPT (p = 0.424).

Conclusions
DAPT beyond 12 months, as compared with 12-month DAPT, patients with AMI treated DES did not reduce the risk of MACCE.